Jubilant Life Sciences is currently trading at Rs. 75.80, up by 0.45 points or 0.60 % from its previous closing of Rs. 75.35 on the BSE.
The scrip opened at Rs. 76.90 and has touched a high and low of Rs. 77.30 and Rs. 75.15 respectively. So far 23002 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 248.25 on 10-Dec-2012 and a 52 week low of Rs. 65.10 on 28-Aug-2013.
Last one week high and low of the scrip stood at Rs. 83.80 and Rs. 74.00 respectively. The current market cap of the company is Rs. 1218.50 crore.
The promoters holding in the company stood at 53.95 % while Institutions and Non-Institutions held 28.41 % and 17.65 % respectively.
Jubilant Life Sciences, an integrated Pharmaceuticals and Life Sciences Company has received Abbreviated New Drug Application (ANDA) approvals from the US Food and Drug Administration (US FDA) for Bupropion Hydrochloride Extended-release Tablets USP (SR), 100 mg, 150 mg and 200 mg, the generic version of GlaxoSmithKline’s antidepressant Wellbutrin SR. The company has also received approval for Bupropion Hydrochloride Extended-release Tablets USP (SR), 150 mg, the generic version of GlaxoSmithKline’s smoking cessation aid, Zyban.
The current total market size for these products as per IMS is $518 million per annum. The company is likely to launch these products in Q3 FY 14. As on June 30, 2013, Jubilant Life Sciences had a total of 649 filings for formulations of which 189 have been approved in various regions of the world. This includes 58 ANDAs filed in the US and 41 Dossier filings in Europe.
Jubilant Life Sciences is a global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1823.60 |
| Dr. Reddys Lab | 1350.00 |
| Cipla | 1490.85 |
| Lupin | 2187.05 |
| Zydus Lifesciences | 981.65 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
